Brief: neffy Approved In Japan As The First Needle-Free Epinephrine Nasal Spray For Emergency Anaphylaxis Treatment
19/09/2025 13:38
Sept 19 (Reuters) - ARS Pharmaceuticals Inc SPRY.O: NEFFY® (EPINEPHRINE NASAL SPRAY) APPROVED IN JAPAN AS THE FIRST AND ONLY NEEDLE-FREE EMERGENCY TREATMENT OF ALLERGIC REACTIONS (ANAPHYLAXIS) ARS PHARMACEUTICALS INC - NEFFY EXPECTED TO BE AVAILABLE IN JAPAN IN Q4 2025 Source text: ID:nGNX9Nf3Jg Further company coverage: SPRY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle